{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T19:58:02Z","timestamp":1792267082427,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuro Oncol"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1093\/neuonc\/nov104","type":"journal-article","created":{"date-parts":[[2015,10,13]],"date-time":"2015-10-13T21:39:34Z","timestamp":1444772374000},"page":"1504-1513","source":"Crossref","is-referenced-by-count":148,"title":["Randomized phase 2 study of carboplatin and bevacizumab in recurrent glioblastoma"],"prefix":"10.1093","volume":"17","author":[{"given":"Kathryn M.","family":"Field","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Simes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lawrence","family":"Cher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Wheeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth J.","family":"Hovey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.B.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth H.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Sawkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Livingstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron","family":"Freilich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pramit M.","family":"Phal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Fitt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"CABARET\/COGNO investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2015,6,30]]},"reference":[{"key":"2015101317425332000_17.11.1504.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra0708126"},{"key":"2015101317425332000_17.11.1504.2","doi-asserted-by":"crossref","unstructured":"Schwartzbaum JA Fisher JL Aldape KD Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2 (9):494\u2013503; quiz 491 p following 516.","DOI":"10.1038\/ncpneuro0289"},{"key":"2015101317425332000_17.11.1504.3","unstructured":"Australian Cancer Network Adult Brain Tumour Guidelines Working Party, Clinical Practice Guidelines for the Management of Adult Gliomas: Astrocytomas and Oligodendrogliomas. Sydney: Cancer Council Australia, Australian Cancer Network and Clinical Oncological Society of Australia Inc., 2009."},{"key":"2015101317425332000_17.11.1504.4","doi-asserted-by":"crossref","unstructured":"Wong ET Hess KR Gleason MJ Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol. 1999;17 (8):2572\u20132578.","DOI":"10.1200\/JCO.1999.17.8.2572"},{"key":"2015101317425332000_17.11.1504.5","doi-asserted-by":"publisher","DOI":"10.1053\/ctrv.2000.0191"},{"key":"2015101317425332000_17.11.1504.6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.47.2464"},{"key":"2015101317425332000_17.11.1504.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309"},{"key":"2015101317425332000_17.11.1504.8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.19.8721"},{"key":"2015101317425332000_17.11.1504.9","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2009-0121"},{"key":"2015101317425332000_17.11.1504.10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.3541"},{"key":"2015101317425332000_17.11.1504.11","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-010-0143-y"},{"key":"2015101317425332000_17.11.1504.12","doi-asserted-by":"crossref","unstructured":"Henriksson R Bottomley A Mason W Progression-free survival (PFS) and health-related quality of life (HRQoL) in AVAglio, a phase III study of bevacizumab (Bv), temozolomide (T), and radiotherapy (RT) in newly diagnosed glioblastoma [abstract2 2005]. J Clin Oncol. 2013;31 (Suppl).","DOI":"10.1200\/jco.2013.31.15_suppl.2005"},{"key":"2015101317425332000_17.11.1504.13","doi-asserted-by":"crossref","unstructured":"Armstrong T Won M Wefel J Comparative impact of treatment on patient reported outcomes (PROs) in patients with glioblastoma (GBM) enrolled in RTOG 0825 [abstract 2003]. J Clin Oncol. 2013;31 (Suppl).","DOI":"10.1200\/jco.2013.31.15_suppl.2003"},{"key":"2015101317425332000_17.11.1504.14","doi-asserted-by":"crossref","unstructured":"Wefel J Pugh S Armstrong T Neurocognitive function (NCF) outcomes in patients with glioblastoma (GBM) enrolled in RTOG 0825 [ abstract 2004}. J Clin Oncol. 2013;31 (Suppl).","DOI":"10.1200\/jco.2013.31.15_suppl.2004"},{"key":"2015101317425332000_17.11.1504.15","doi-asserted-by":"crossref","unstructured":"Yung WK Mechtler L Gleason MJ . Intravenous carboplatin for recurrent malignant glioma: a phase II study. J Clin Oncol. 1991;9 (5):860\u2013864.","DOI":"10.1200\/JCO.1991.9.5.860"},{"key":"2015101317425332000_17.11.1504.16","doi-asserted-by":"publisher","DOI":"10.1007\/BF01051050"},{"key":"2015101317425332000_17.11.1504.17","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-011-0722-2"},{"key":"2015101317425332000_17.11.1504.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2009.12.009"},{"key":"2015101317425332000_17.11.1504.19","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events version 4.0. Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm - ctc_40 Accessed July 2014."},{"key":"2015101317425332000_17.11.1504.20","doi-asserted-by":"publisher","DOI":"10.1227\/01.NEU.0000370918.51053.BC"},{"key":"2015101317425332000_17.11.1504.21","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.2440"},{"key":"2015101317425332000_17.11.1504.22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.3055"},{"key":"2015101317425332000_17.11.1504.23","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.26381"},{"key":"2015101317425332000_17.11.1504.24","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70314-6"},{"key":"2015101317425332000_17.11.1504.25","doi-asserted-by":"crossref","unstructured":"Mrugala MM Crew LK Fink JR Carboplatin and bevacizumab for recurrent malignant glioma. Oncol Lett. 2012;4 (5):1082\u20131086.","DOI":"10.3892\/ol.2012.839"},{"key":"2015101317425332000_17.11.1504.26","doi-asserted-by":"publisher","DOI":"10.3171\/2008.4.17492"},{"key":"2015101317425332000_17.11.1504.27","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25462"},{"key":"2015101317425332000_17.11.1504.28","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou021"},{"key":"2015101317425332000_17.11.1504.29","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou150"}],"container-title":["Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/neuro-oncology\/article-pdf\/17\/11\/1504\/16665632\/nov104.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T14:48:26Z","timestamp":1599662906000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/neuro-oncology\/article-lookup\/doi\/10.1093\/neuonc\/nov104"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,30]]},"references-count":29,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,10,9]]},"published-print":{"date-parts":[[2015,11]]}},"alternative-id":["10.1093\/neuonc\/nov104"],"URL":"https:\/\/doi.org\/10.1093\/neuonc\/nov104","relation":{},"ISSN":["1522-8517","1523-5866"],"issn-type":[{"value":"1522-8517","type":"print"},{"value":"1523-5866","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,6,30]]}}}